MiMedx Group logo
MiMedx Group MDXG
$ 4.41 0.0%

Annual report 2025
added 02-25-2026

report update icon

MiMedx Group Income Statement 2011-2026 | MDXG

Annual Income Statement MiMedx Group

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

779 M 1.18 B 954 M 542 M 547 M 1.06 B 791 M 276 M 2.06 B - - - - 354 M 81.2 M

Shares

148 M 147 M 116 M 113 M 110 M 108 M 107 M 106 M 116 M - - - - 81.6 M 72.5 M

Historical Prices

5.27 8 8.19 4.8 4.96 9.82 7.38 2.64 16.8 8.08 8.32 8.15 7.84 4.35 1.15

Net Income

48.6 M 42.4 M 58.2 M -30.2 M -10.3 M -49.3 M -25.6 M -30 M 64.7 M 390 K 29.4 M 6.22 M -4.11 M -7.66 M -10.2 M

Revenue

419 M 349 M 321 M 268 M 242 M 248 M 299 M 359 M 321 M 222 M 187 M 118 M 59.2 M 27.1 M 7.8 M

Cost of Revenue

73 M 60.1 M 54.6 M 48.3 M 39.6 M 39.3 M 43.1 M 36.4 M 35.2 M 30.9 M - - - - -

Gross Profit

346 M 289 M 267 M 220 M 202 M 209 M 256 M 323 M 286 M 192 M 167 M 106 M 49.9 M 21.9 M 4.6 M

Operating Income

63.9 M 58.9 M 37.1 M -14.7 M -7.05 M -45.4 M -21.2 M -3.92 M 46.2 M 884 K 24.4 M 7.1 M -2.64 M -5.36 M -9.76 M

Interest Expense

-558 K -565 K -26 K -4 K -23 K -3 K 283 K - - 339 K 86 K 48 K 45.2 K 593 K 433 K

EBITDA

78.8 M 64.9 M 40.5 M -11.4 M -2.69 M -39.6 M -13.6 M 2.99 M 50.9 M 6.35 M 27.1 M 9.22 M -947 K -3.51 M -8.01 M

Operating Expenses

- - - - - - 277 M 327 M 240 M 194 M 143 M 98.5 M 52.1 M 23.9 M 14.4 M

General and Administrative Expenses

56.5 M 49.5 M 49.3 M 57.4 M 195 M 181 M 194 M 253 M 216 M 170 M 133 M 90.5 M 46.2 M 19.6 M 11.8 M

All numbers in USD currency

Quarterly Income Statement MiMedx Group

2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

148 M 147 M 147 M 147 M 147 M 146 M 146 M 116 M 116 M 114 M 114 M 113 M 113 M 112 M 112 M 111 M 110 M 109 M 111 M 108 M 108 M 108 M 111 M 107 M 107 M 106 M 109 M 106 M 106 M 105 M 109 M 107 M 107 M 106 M 110 M 106 M 106 M 106 M 107 M 107 M 106 M 106 M 108 M 106 M 106 M 105 M 104 M 96.9 M 96 M 93.1 M 88.4 M 84.5 M 80 M 74.9 M 74.3 M 73.8 M 71.8 M 74.3 M

Net Income

9.62 M 7.02 M - 8.1 M 17.6 M 9.26 M - 8.53 M 1.2 M -4.98 M - -8.43 M -10.9 M -10.5 M - -2.34 M -1.78 M -8.38 M -16.6 M -19.4 M -8.47 M -4.82 M -7.48 M 12.4 M -17.2 M -13.3 M -36.2 M -178 K 1.8 M 4.62 M 4.28 M 44.1 M 10.4 M 6 M 5.48 M 3.32 M 1.98 M 1.2 M 13.4 M 6.55 M 5.43 M 4.09 M 3.83 M 3.7 M -390 K -922 K -1.43 M -307 K -757 K -1.62 M -1.6 M -4.22 M -744 K -1.09 M -2.58 M -1.77 M -2.5 M -3.35 M

Revenue

98.6 M 88.2 M - 84.1 M 87.2 M 84.7 M - 81.7 M 81.3 M 71.7 M - 67.7 M 66.9 M 58.9 M - 63.1 M 68.2 M 60 M 68.5 M 64.3 M 53.6 M 61.7 M 76.4 M 88.9 M 67.4 M 66.6 M 92.6 M 87 M 95.4 M 84.1 M 87.9 M 84 M 80.5 M 68.8 M - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

18.7 M 16.6 M - 15.3 M 14.9 M 13 M - 14.8 M 13.6 M 12.4 M - 12.2 M 11.8 M 9.94 M - 10.1 M 12.8 M 9.64 M - 10.3 M 8.2 M 10 M - 13.2 M 9.75 M 7.42 M - 7.36 M 9.27 M 9.36 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

79.9 M 71.6 M - 68.7 M 72.4 M 71.7 M - 66.9 M 67.7 M 59.3 M - 55.5 M 55.1 M 49 M - 52.9 M 55.4 M 50.3 M 57.7 M 54 M 45.4 M 51.7 M 63.7 M 75.7 M 57.7 M 59.1 M 82.2 M 79.6 M 86.1 M 74.8 M 78.5 M 74.7 M 72 M 60.8 M 60.8 M 56.4 M 49.9 M 45.4 M 46.8 M 44 M 40.6 M 35.6 M 36 M 30.2 M 22.8 M 16.6 M 14.9 M 14 M 11.3 M 9.65 M 8.82 M 6.53 M 3.77 M 2.75 M 1.72 M 1.27 M 1.08 M 333 K

Operating Income

12.4 M 8.25 M - 11.2 M 23.4 M 13.2 M - 11.1 M 10.8 M -340 K - -7.1 M -9.64 M -9.3 M - -1.08 M -410 K -6.85 M - -9.71 M -5.86 M -13.7 M - 14.2 M -17.1 M -13.4 M - 373 K 1.68 M 2.97 M - 8.84 M 7.21 M 6.18 M - 4.7 M 3.56 M 1.47 M - 6.71 M 5.65 M 4.25 M - 3.73 M -392 K -891 K - -256 K -744 K -227 K - -3.63 M -118 K -631 K - -1.65 M -2.42 M -3.26 M

Interest Expense

-101 K -145 K - -21 K -237 K -99 K - -11 K -32 K 2 K - - - -1.13 M - - -3 K - - 1 K -9 K 6 K - 127 K 174 K -29 K - - - - - -43 K -149 K -145 K - -87 K -111 K -56 K - -5 K 1 K 14 K - 9.13 K 8.43 K 21 K - 4.53 K 13.2 K 14.8 K - 146 K 154 K 152 K - 32.7 K 26.5 K 91.2 K

EBITDA

12.9 M 8.81 M - 11.4 M 24 M 13.8 M - 11.3 M 11 M 374 K - -6.27 M -8.78 M -8.44 M - -152 K 896 K -5.69 M - -8.14 M -4.43 M -12.2 M - 15.8 M -15.5 M -11.7 M - 1.77 M 2.98 M 4.19 M - 9.86 M 8.33 M 7.13 M - 5.54 M 4.38 M 2.2 M - 7.18 M 6.07 M 4.6 M - 4.04 M -104 K -628 K - -70.9 K -605 K -128 K - -3.28 M 114 K -521 K - -1.32 M -2.18 M -3.14 M

General and Administrative Expenses

16.3 M 13.1 M - 53.5 M 13.7 M 10.7 M - 52.6 M 52 M 52.2 M - 53.5 M 55.8 M 49.6 M - 46.3 M 53.6 M 45.4 M - 48 M 37.3 M 46.9 M - 51.3 M 50.6 M 50.9 M - 58.7 M 67.6 M 65.9 M - 60.2 M 55.3 M 53 M - 48.2 M 42.8 M 40.6 M - 34.9 M 32.7 M 29.3 M - 24.2 M 21.2 M 15.9 M - 12.7 M 10.9 M 8.37 M - 5.76 M 3.05 M 2.64 M - 2.36 M 2.71 M 2.63 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company MiMedx Group (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Aethlon Medical Aethlon Medical
AEMD
$ 2.11 - $ 3.29 M usaUSA
AdaptHealth Corp. AdaptHealth Corp.
AHCO
$ 10.42 - $ 1.41 B usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Butterfly Network Butterfly Network
BFLY
$ 3.91 - $ 828 M usaUSA
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
CONMED Corporation CONMED Corporation
CNMD
$ 37.41 - $ 1.16 B usaUSA
Alphatec Holdings Alphatec Holdings
ATEC
$ 12.6 - $ 1.89 B usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Cognyte Software Ltd. Cognyte Software Ltd.
CGNT
$ 8.38 - $ 602 M israelIsrael
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
$ 3.96 1.02 % $ 148 M franceFrance
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Boston Scientific Corporation Boston Scientific Corporation
BSX
$ 69.79 - $ 103 B usaUSA
Establishment Labs Holdings Establishment Labs Holdings
ESTA
$ 63.48 - $ 1.88 B costa-ricaCosta-rica
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Helius Medical Technologies Helius Medical Technologies
HSDT
$ 2.19 - $ 1.33 M usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.65 -8.13 % $ 35.4 M usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 1.33 - $ 21.5 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 11.03 - $ 298 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
LivaNova PLC LivaNova PLC
LIVN
$ 61.43 - $ 3.35 B britainBritain
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
FONAR Corporation FONAR Corporation
FONR
$ 18.42 0.22 % $ 121 M usaUSA
InMode Ltd. InMode Ltd.
INMD
$ 13.43 - $ 868 M israelIsrael
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
Nano-X Imaging Ltd. Nano-X Imaging Ltd.
NNOX
$ 2.59 - $ 152 M israelIsrael
Abbott Laboratories Abbott Laboratories
ABT
$ 109.95 - $ 191 B usaUSA
Delcath Systems Delcath Systems
DCTH
$ 9.81 - $ 351 M usaUSA
Bio-Rad Laboratories Bio-Rad Laboratories
BIO
$ 261.24 - $ 7.37 B usaUSA
Insulet Corporation Insulet Corporation
PODD
$ 224.66 - $ 15.8 B usaUSA
Integra LifeSciences Holdings Corporation Integra LifeSciences Holdings Corporation
IART
$ 9.01 - $ 694 M usaUSA
Profound Medical Corp. Profound Medical Corp.
PROF
$ 5.71 - $ 180 M canadaCanada
AxoGen AxoGen
AXGN
$ 32.84 - $ 1.51 B usaUSA
Align Technology Align Technology
ALGN
$ 169.45 - $ 12.7 B usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 32.76 - $ 4.88 K usaUSA
AVITA Medical AVITA Medical
RCEL
$ 4.62 5.0 % $ 129 M australiaAustralia